After almost two decades of stagnation, two new drugs for Alzheimer’s have hit the market in the last three years. The approval of Biogen…
The FDA rejected Eli Lilly’s request to expedite the approval process for experimental Alzheimer’s drug donanemab, but the drug’s Phase 3 trial is carrying…
In Being Patient’s LiveTalk series, Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, shares insights on Eli Lilly’s investigational Alzheimer’s…
We talked with Banner Alzheimer’s Institute Director Pierre Tariot about the most recent results from Eli Lilly’s Alzheimer’s trial for donanemab — what he…
This weekend, new batch of data from the TRAILBLAZER-ALZ trial for Eli Lilly’s Alzheimer’s drug donanemab was released, upholding the treatment’s ability to affect…
While Biogen’s experimental Alzheimer’s treatment aducanumab faced yet another snag recently in its convoluted path toward FDA approval, other drugs companies are catching up:…
Recently, Eli Lilly announced that their anti-amyloid drug solanezumab failed to prevent Alzheimer’s in cognitively healthy older individuals who showed amyloid plaque accumulation in…
Scientists still don’t know what causes Alzheimer’s, but they do have one, long-standing theory: the amyloid hypothesis. Some say it’s on the brink of…
Drugmaker Eli Lilly says experimental Alzheimer’s drug remternetug is part of the next generation of anti-amyloids. The approval of the controversial anti-amyloid drug Aduhelm…
Canine cognitive dysfunction looks a lot like Alzheimer’s and dementia in humans. Could a disease-modifying intervention that seems effective our furry companions also work for…
Bombshell exposé in Science magazine and follow-up reporting “make a mountain out of a molehill,” leading Alzheimer’s experts say. The media is reporting that…
Scientists screened 595 FDA-approved drugs to see if they interfered with the activity of gene mutation ApoE4. Two of these — antidepressant imipramine and…
New findings reveal that the way Aduhelm is packaged leads to wasted medication — and as much as $605 million per year of Medicare…
Vaxxinity’s beta-amyloid vaccine to treat Alzheimer’s disease — UB-311 — recently received fast track designation as it finishes up Phase 2 trials. Image: Vaxxinity…
Human clinical trials kick off for Protollin, an experimental Alzheimer’s vaccine. After two decades of research and development, Brigham and Women’s Hospital has initiated…